A patient with bipolar disorder has been taking valproate with only partial control of depressive symptoms. The PMHNP decides to add lamotrigine to the regimen, as the patient reports he has been stabilized on this combination in the past. Compared to lamotrigine monotherapy, what adjustments should be made to the lamotrigine titration schedule and why?

A. Slow titration with half the target dose. Valproate inhibits lamotrigine metabolism, increasing plasma levels and the risk of serious cutaneous reactions, including Stevens-Johnson Syndrome. Starting at half the usual target dose and titrating slowly reduces this risk while allowing therapeutic efficacy. B. Slow titration with one-fourth of the target dose. Valproate does increase lamotrigine levels, but urinary tract infections are not a known risk from this interaction. The key concern is serious dermatologic reactions, not infections. C. Slow titration with half the target dose. Lamotrigine does not significantly raise valproate levels. The pharmacokinetic concern is unidirectional, with valproate increasing lamotrigine levels, not the reverse. D. Rapid titration with the full target dose. Rapid titration increases the risk of severe rash, including Stevens-Johnson Syndrome. Lamotrigine does not substantially alter valproate metabolism, so this approach is unsafe and inappropriate.